Clinical Trial: Re-Irradiation of Progressive or Recurrent DIPG
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: ReRAD: A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma
Brief Summary: This is a single-arm, non-randomized study of re-irradiation of diffuse intrinsic pontine glioma (DIPG)
Detailed Summary: Study therapy will consist of radiation therapy (RT) given over 17 treatment days (for 30.6 Gy in fractions of 1.8 Gy) or 20 treatment days (for 36 Gy in 1.8 Gy fractions), depending on the time from completion of the first course of RT. Treatment days will generally be weekdays, not including statutory holidays.
Sponsor: University of Calgary
Current Primary Outcome: second progression-free survival [ Time Frame: up to 18 months from the start of re-irradiation ]
Original Primary Outcome: Same as current
Current Secondary Outcome: overall survival [ Time Frame: up to three years from initial diagnosis of DIPG ]
Original Secondary Outcome: Same as current
Information By: University of Calgary
Dates:
Date Received: April 19, 2017
Date Started: June 1, 2017
Date Completion: October 2021
Last Updated: April 19, 2017
Last Verified: March 2017